{"id":47062,"topic":"peptides","source":"搜狐网","title":"多肽药物的下一场革命，开始了 - 搜狐网","url":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","url_hash":"95faaebc103799d7a48b8ba2cc47c4d9b91b7ef5","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNNHBycnF3cUFwWDREZi11cmpBUHBlS1Mya2dvQ1pPeHVpc1FpblRlSE1DTFZYY29ZWDlEd2hCS3RKUVlrNVVXbFdhbkJCS1N0VmNTaWZ5YmZIdzdKRG4zc3gxYl9NMjV5ejdmU1VwTFJmSVRqSFZESHFWdjlDaHBlb2p3R3Y3VnZU?oc=5\" target=\"_blank\">多肽药物的下一场革命，开始了</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">搜狐网</font>","content":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","image_url":"https://q6.itc.cn/q_70/images03/20260727/0c0c2171451b40ce8b52f2c59411d637.png","lang":"zh","published_at":"2026-07-27T03:25:13+00:00","fetched_at":"2026-07-27T10:15:12+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 479 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":479,"summary_length":479,"usable_text_length":479,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":479,"summary_length":479}},"news_item":{"id":47062,"canonical_url":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source_url":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","title":"多肽药物的下一场革命，开始了 - 搜狐网","source_name":"搜狐网","author":null,"published_at":"2026-07-27T03:25:13+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNNHBycnF3cUFwWDREZi11cmpBUHBlS1Mya2dvQ1pPeHVpc1FpblRlSE1DTFZYY29ZWDlEd2hCS3RKUVlrNVVXbFdhbkJCS1N0VmNTaWZ5YmZIdzdKRG4zc3gxYl9NMjV5ejdmU1VwTFJmSVRqSFZESHFWdjlDaHBlb2p3R3Y3VnZU?oc=5\" target=\"_blank\">多肽药物的下一场革命，开始了</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">搜狐网</font>","full_text":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","excerpt":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 479 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1055220286_116132%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 479 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":479,"summary_length":479,"usable_text_length":479,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":479,"summary_length":479}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"多肽药物的下一场革命，开始了 - 搜狐网","url":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","source":"搜狐网","date":"2026-07-27T03:25:13+00:00","content":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1055220286_116132%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 479 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 479 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":479,"summary_length":479,"usable_text_length":479,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":479,"summary_length":479}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/47062","export_markdown":"/api/items/47062/export?format=markdown","export_json":"/api/items/47062/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1055220286_116132%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"formats":{"full":{"id":47062,"title":"多肽药物的下一场革命，开始了 - 搜狐网","url":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"搜狐网","author":null,"published_at":"2026-07-27T03:25:13+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","full_text":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 479 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1055220286_116132%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 479 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":479,"summary_length":479,"usable_text_length":479,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":479,"summary_length":479}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 479 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":479,"summary_length":479,"usable_text_length":479,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":479,"summary_length":479}},"actions":{"read":"/item/47062","export_markdown":"/api/items/47062/export?format=markdown","export_json":"/api/items/47062/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1055220286_116132%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"}},"digest":{"id":47062,"title":"多肽药物的下一场革命，开始了 - 搜狐网","url":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"搜狐网","topic":"peptides","published_at":"2026-07-27T03:25:13+00:00","excerpt":"多肽药物的下一场革命，开始了 文 | 氨基观察 多肽药物的下一场革命已经到来 GLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。 从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。 环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。 更重要的是，环肽让多肽药物口服成为可能。…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 479 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"多肽药物的下一场革命，开始了 - 搜狐网","subtitle":"搜狐网 · 2026-07-27","summary":"多肽药物的下一场革命，开始了 文 | 氨基观察 多肽药物的下一场革命已经到来 GLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。 从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。 环状肽（cyclic…","badges":["quality:high"],"links":{"read":"/item/47062","original":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1055220286_116132%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"quality_warning":null},"export":{"title":"多肽药物的下一场革命，开始了 - 搜狐网","url":"https://m.sohu.com/a/1055220286_116132?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","source":"搜狐网","date":"2026-07-27T03:25:13+00:00","content":"多肽药物的下一场革命，开始了\n文 | 氨基观察\n多肽药物的下一场革命已经到来\nGLP-1的爆发，让多肽药物彻底迎来了百亿美元市场的黄金时代。\n从司美格鲁肽到替尔泊肽，GLP-1不断拉高多肽药物的价值天花板，让市场看到了多肽药物的潜力。而在商业化爆发的同时，多肽技术层面的迭代也在同步推进。\n环状肽（cyclic peptide）正是这一轮技术进化的核心方向之一。相比传统线性多肽，环肽通过优化构象和药代动力学特征提高分子稳定性，使其不仅能够保持多肽对复杂靶点的高选择性识别能力，同时进一步突破成药性瓶颈。\n更重要的是，环肽让多肽药物口服成为可能。\n凭借结构刚性带来的酶解稳定性与膜通透性提升，环肽首次让口服大分子多肽具备了成药可能。随着强生的Icotrokinra（ICOTYDE）、默沙东Enlicitide（Lipfendra）两款药物相继获批上市，口服多肽药物正式来到商业化元年。\n尽管当前口服环肽的疗效与注射剂型仍有差距，口服生物利用度也存在较大优化空间，但这并未阻挡产业资本的涌入。越来越多药企和Biotech开始加速布局，相关BD交易也持续升温。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1055220286_116132%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 479 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 479 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":479,"summary_length":479,"usable_text_length":479,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":479,"summary_length":479}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}